CDK19/CCNC(CDK19/cyclin C)
Sign in to save this workspaceUniProt CDK19: Q9BWU1; Cyclin C: P24863 · PDB · AlphaFold (Q9BWU1), AlphaFold (P24863) · Substrate: Pol2-CTD · Clone: aa 1-502/aa 1-283
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Midostaurin | 90.2% | 9.8% | 78.64 | 0.500 |
| 2 | Brigatinib | 87.7% | 12.3% | 82.96 | 0.513 |
| 3 | Sunitinib | 79.6% | 20.4% | 91.73 | 0.524 |
| 4 | Abemaciclib | 78.6% | 21.4% | 91.48 | 0.563 |
| 5 | Bosutinib | 76.6% | 23.4% | 87.22 | 0.555 |
| 6 | Alectinib | 70.5% | 29.5% | 95.49 | 0.651 |
| 7 | Nintedanib | 66.9% | 33.1% | 90.23 | 0.608 |
| 8 | Ruxolitinib | 66.6% | 33.4% | 98.25 | 0.592 |
| 9 | Gilteritinib | 65.7% | 34.3% | 88.97 | 0.506 |
| 10 | Baricitinib | 64.2% | 35.8% | 97.99 | 0.616 |
| 11 | Ribociclib | 46.5% | 53.5% | 99.25 | 0.729 |
| 12 | Palbociclib | 43.9% | 56.1% | 98.75 | 0.673 |
| 13 | Lorlatinib | 33.5% | 66.5% | 97.24 | 0.694 |
| 14 | Gefitinib | 25.3% | 74.7% | 99.25 | 0.650 |
| 15 | Axitinib | 22.4% | 77.6% | 93.23 | 0.688 |
| 16 | Osimertinib | 18.3% | 81.7% | 97.24 | 0.733 |
| 17 | Afatinib | 17.9% | 82.1% | 98.50 | 0.709 |
| 18 | Dacomitinib | 12.5% | 87.5% | 97.99 | 0.664 |
| 19 | Vemurafenib | 11.1% | 88.9% | 96.49 | 0.598 |
| 20 | Larotrectinib | 10.1% | 89.9% | 99.25 | 0.710 |
Paralog block
No paralog group registered for this kinase.
EMT expression
Not in the EMT expression panel.
Selectivity landscape vs inhibition on CDK19/CCNC
Each point is one of the 92 approved drugs; color = inhibition % on CDK19/CCNC.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…